CCL2 and breast carcinoma: Hence, it is noteworthy that anti-CCL2 antibody or bindarit is attractive to suppress with the CCL2/CCR2 axis, since it reduced tumor multiplicity in the C3(1)/SV40Tag mouse model of breast cancer by inhibition of inflammatory mediators and macrophage markers [209].